These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24548695)

  • 41. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
    Elrashidy RA; Asker ME; Mohamed HE
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):324-33. PubMed ID: 22261714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes.
    Pharaon LF; El-Orabi NF; Kunhi M; Al Yacoub N; Awad SM; Poizat C
    Toxicol Lett; 2017 Oct; 280():151-158. PubMed ID: 28822817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rosiglitazone and delayed onset of proliferative diabetic retinopathy.
    Shen LQ; Child A; Weber GM; Folkman J; Aiello LP
    Arch Ophthalmol; 2008 Jun; 126(6):793-9. PubMed ID: 18541841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats.
    Saito S; Teshima Y; Fukui A; Kondo H; Nishio S; Nakagawa M; Saikawa T; Takahashi N
    Cardiovasc Res; 2014 Oct; 104(1):5-14. PubMed ID: 25082849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.
    Wu L; Wang R; De Champlain J; Wilson TW
    Am J Hypertens; 2004 Sep; 17(9):749-56. PubMed ID: 15363815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conjugated linoleic acid prevents high glucose-induced hypertrophy and contractile dysfunction in adult rat cardiomyocytes.
    Aloud BM; Raj P; O'Hara K; Shao Z; Yu L; Anderson HD; Netticadan T
    Nutr Res; 2016 Feb; 36(2):134-42. PubMed ID: 26826429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
    Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats.
    Torres TS; D'Oliveira Silva G; Aguila MB; de Carvalho JJ; Mandarim-De-Lacerda CA
    Hypertens Res; 2008 May; 31(5):965-75. PubMed ID: 18712052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet.
    Murthy SN; Obregon DF; Chattergoon NN; Fonseca NA; Mondal D; Dunne JB; Diez JG; Jeter JR; Kadowitz PJ; Agrawal KC; McNamara DB; Fonseca VA
    Metabolism; 2005 May; 54(5):645-52. PubMed ID: 15877295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
    Zhang Y; Edgley AJ; Cox AJ; Powell AK; Wang B; Kompa AR; Stapleton DI; Zammit SC; Williams SJ; Krum H; Gilbert RE; Kelly DJ
    Eur J Heart Fail; 2012 May; 14(5):549-62. PubMed ID: 22417655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart.
    Karam CN; Nuwayri-Salti N; Usta JA; Zwainy DS; Abrahamian RE; Al Jaroudi WA; Baasisri MJ; Abdallah SM; Bitar KM; Bikhazi AB
    Endothelium; 2005; 12(5-6):225-31. PubMed ID: 16410221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts.
    Al Lafi SM; Artinian SB; Boutary SS; Zwainy NS; Bitar KM; Bikhazi AB
    Can J Physiol Pharmacol; 2013 Oct; 91(10):830-8. PubMed ID: 24144054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
    Hou X; Zhang Y; Shen YH; Liu T; Song S; Cui L; Bu P
    Eur J Pharmacol; 2013 Sep; 715(1-3):196-203. PubMed ID: 23791613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
    Liu Y; Chewchuk S; Lavigne C; Brûlé S; Pilon G; Houde V; Xu A; Marette A; Sweeney G
    Am J Physiol Endocrinol Metab; 2009 Sep; 297(3):E657-64. PubMed ID: 19531641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes.
    Pang W; Li N; Ai D; Niu XL; Guan YF; Zhu Y
    Clin Exp Pharmacol Physiol; 2011 Jun; 38(6):358-64. PubMed ID: 21291492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin.
    Sahin K; Tuzcu M; Orhan C; Sahin N; Kucuk O; Ozercan IH; Juturu V; Komorowski JR
    Br J Nutr; 2013 Jul; 110(2):197-205. PubMed ID: 23211098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.